{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057443","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.819010+00:00","generated_at":"2026-06-02T04:11:53.885528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProKidney reports Q1 net loss $35.3M, cash $329M; Phase 2 data to be presented May 25","bullets":["RMCL-002 Phase 2 final results to be presented at ERA Congress on May 25, 2024; investor call on May 28.","PROACT 1 protocol amendment submitted to FDA focusing on severe CKD (eGFR 20-35); enrollment to resume mid-2024.","Appointed Ulrich Ernst as EVP Technical Operations and Lucio Tozzi as SVP Global Clinical Operations.","Cash and equivalents $329M as of March 31, 2024, supporting operations into Q4 2025.","Net loss before noncontrolling interest $35.3M for Q1 2024 vs $36.9M same period 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057443","json":"https://secwatch.observer/filing/0000950170-24-057443.json","markdown":"https://secwatch.observer/filing/0000950170-24-057443.md","text":"https://secwatch.observer/filing/0000950170-24-057443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/0000950170-24-057443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/prok-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:11:53.885528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa6ee748f98eed67dfd2d733db8dedd601cd0eae","claim":"PROKIDNEY CORP. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 10, 2024, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/0000950170-24-057443-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}